| Literature DB >> 33035176 |
Heather Leslie1,2.
Abstract
BACKGROUND: Despite electronic health records being in existence for over 50 years, our ability to exchange health data remains frustratingly limited. Commonly used clinical content standards, and the information models that underpin them, are primarily related to health data exchange, and so are usually document- or message-focused. In contrast, over the past 12 years, the Clinical Models program at openEHR International has gradually established a governed, coordinated, and coherent ecosystem of clinical information models, known as openEHR archetypes. Each archetype is designed as a maximal data set for a universal use-case, intended for reuse across various health data sets, known as openEHR templates. To date, only anecdotal evidence has been available to indicate if the hypothesis of archetype reuse across templates is feasible and scalable. As a response to the COVID-19 pandemic, between February and July 2020, 7 openEHR templates were independently created to represent COVID-19-related data sets for symptom screening, confirmed infection reporting, clinical decision support, and research. Each of the templates prioritized reuse of existing use-case agnostic archetypes found in openEHR International's online Clinical Knowledge Manager tool as much as possible. This study is the first opportunity to investigate archetype reuse within a range of diverse, multilingual openEHR templates.Entities:
Keywords: COVID-19; EHR; SARS-CoV-2; archetype; clinical informatics; crowd sourced; data quality; data set; electronic health record; multilingual; openEHR; reuse; standard; template
Mesh:
Year: 2020 PMID: 33035176 PMCID: PMC7641651 DOI: 10.2196/23361
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Reuse per template.
| Variable | Template | |||||||
|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Total data points, n | 60 | 88 | 40 | 102 | 179 | 129 | 124 | |
| Archetype instances, n | 15 | 21 | 16 | 26 | 62 | 10 | 53 | |
| Unique archetype occurrences, n | 10 | 14 | 16 | 16 | 17 | 10 | 28 | |
|
| 40 | 52 | 100 | 100 | 100 | 80 | 100 | |
|
| Existing archetype reuse, n/N (%) | 6/15 (40) | 11/21 (52) | 13/16 (81) | 16/26 (62) | 56/62 (90) | 5/10 (50) | 30/53 (57) |
|
| New archetype reuse, n/N (%) | 0/15 (0) | 0/21 (0) | 3/16 (19) | 10/26 (38) | 6/62 (10) | 3/10 (30) | 23/53 (43) |
|
| COVID-19–specific archetype use, n/N (%) | 9/15 (60) | 10/21 (48) | 0/16 (0) | 0/26 (0) | 0/62 (0) | 2/10 (20) | 0/53 (0) |
Reuse per archetype (total number of archetype instances=203).
| Archetype concept name | Publication statusa | Template | Archetype reuse | Template count | |||||||
|
|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|
| |
|
| |||||||||||
|
| Laboratory test result | P |
| 2 |
| 2 | 15 |
| 5 |
|
|
|
| Laboratory analyte result | P |
|
|
|
| 15 |
| 4 |
|
|
|
| Specimen | P |
|
|
|
| 15 |
|
|
|
|
|
| Address | D |
| 3 | 1 | 3 |
|
|
|
|
|
|
| Problem/diagnosis | P | 1 |
| 1 | 2 |
|
| 3 |
|
|
|
| Health risk assessment | P |
|
| 1 | 4 |
| 1 |
|
|
|
|
| Story/History | P | 1 | 2 | 1 | 1 |
| 1 |
|
|
|
|
| Body temperature | P | 1 |
| 1 |
| 1 |
| 1 |
|
|
|
| Encounter | P | 1 |
| 1 |
|
| 1 |
|
|
|
|
| Facility | D |
| 1 | 1 | 1 |
|
|
|
|
|
|
| Occupation record | P |
| 1 | 1 | 1 |
|
|
|
|
|
|
| Occupation summary | P |
| 1 | 1 | 1 |
|
|
|
|
|
|
| Imaging test result | D |
|
|
|
| 2 |
| 1 |
|
|
|
| Problem/diagnosis qualifier | P | 1 |
| 1 |
|
|
| 1 |
|
|
|
| Dwelling | D |
|
| 1 |
|
| 1 |
|
|
|
|
| Living arrangement | D |
|
| 1 |
|
| 1 |
|
|
|
|
| Imaging finding | D |
|
|
|
| 2 |
|
|
|
|
|
| Report | P |
| 1 |
| 1 |
|
|
|
|
|
|
| Service request | P | 1 |
| 1 |
|
|
|
|
|
|
|
| Inspired oxygen | P |
|
|
|
| 1 |
| 1 |
|
|
|
| Pulse oximetry | P |
|
|
|
| 1 |
| 1 |
|
|
|
| Respiration | P |
|
|
|
| 1 |
| 1 |
|
|
|
| Symptom/sign | P |
|
|
|
|
|
| 1 |
|
|
|
| Age | D |
|
|
|
| 1 |
|
|
|
|
|
| Pulse | P |
|
|
|
|
|
| 1 |
|
|
|
| Blood pressure | P |
|
|
|
|
|
| 1 |
|
|
|
| Differential diagnoses | R |
|
|
|
| 1 |
|
|
|
|
|
| SOFAc score | D |
|
|
|
|
|
| 1 |
|
|
|
| PaO2/FiO2 ratio | P |
|
|
|
| 1 |
|
|
|
|
|
| Tobacco smoking summary | P |
|
|
|
|
|
| 1 |
|
|
|
| Exclusion - specific | P |
|
|
|
|
|
| 1 |
|
|
|
| Gender | P |
|
|
|
|
|
| 1 |
|
|
|
| Clinical frailty score | P |
|
|
|
|
|
| 1 |
|
|
|
| Body weight | P |
|
|
|
|
|
| 1 |
|
|
|
| Body height | P |
|
|
|
|
|
| 1 |
|
|
|
| Resuscitation status –United Kingdom | D |
|
|
|
|
|
| 1 |
|
|
|
| Medication summary | D |
|
|
|
|
|
| 1 |
|
|
|
| |||||||||||
|
| Condition screening questionnaire | D |
|
|
| 1 | 1 |
| 12 |
|
|
|
| Symptom/sign screening questionnaire | D |
|
| 1 | 2 | 1 | 1 | 1 |
|
|
|
| Management screening questionnaire | D |
|
|
| 2 | 1 |
| 3 |
|
|
|
| Travel event | D |
|
| 1 | 1 |
| 1 | 1 |
|
|
|
| Medication screening questionnaire | D |
|
|
|
|
|
| 4 |
|
|
|
| Overcrowding screening | D |
|
| 1 |
|
| 1 |
|
|
|
|
| Exposure assessment questionnaire | D |
|
|
|
| 1 |
| 1 |
|
|
|
| Procedure screening questionnaire | D |
|
|
| 2 |
|
|
|
|
|
|
| Therapeutic order | D |
|
|
|
| 2 |
|
|
|
|
|
| Episode of care | D |
|
|
| 1 |
|
| 1 |
|
|
|
| Infectious exposure investigation | D |
|
|
| 1 |
|
|
|
|
|
|
| |||||||||||
|
| Symptom/sign – COVID-19 | X | 6 | 2 |
|
|
|
|
|
|
|
|
| Admission | X |
| 2 |
|
|
|
|
|
|
|
|
| Outbreak exposure | X | 1 | 1 |
|
|
|
|
|
|
|
|
| Procedure summary | X |
| 2 |
|
|
|
|
|
|
|
|
| Travel trip history | X | 1 | 1 |
|
|
|
|
|
|
|
|
| Comorbidity summary | X |
| 1 |
|
|
|
|
|
|
|
|
| COVID outcomes | X |
| 1 |
|
|
|
|
|
|
|
|
| Fever ( | X |
|
|
|
|
| 1 |
|
|
|
|
| Health risk assessment –COVID-19 | X | 1 |
|
|
|
|
|
|
|
|
|
| Social summary COVID-19 | X |
|
|
|
|
| 1 |
|
|
|
aThe publication status key is: P=content is published; R=content is undergoing peer review; D=draft candidate; X=ungoverned, specific use-case only.
bImportant values are italicized.
cSOFA: sequential organ failure assessment score.